Direct current neuromodulation and its benefits in different populations
- Conditions
- Chikungunya feverarthralgiaC02.782.930.100.184C05.550.091
- Registration Number
- RBR-5fh5r4
- Lead Sponsor
- niversidade Federal do Rio Grande do Norte
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Man or woman aged 18 or older; be in chronic phase of chikungunya fever (least 3 month of the initial infection) and show laboratory tests or clinical diagnostic confirmation of chikungunya virus; pain related with more than 4 in a numeric rating scale; to have physical capacity to do physical evaluation and be capable of consenting to treatment and understanding study explanations and questionnaires; having provided informed consent
Electrical implants in the body; a history of epilepsy; people who are clinically contraindicated to receive tDCS such as having metal embedded in their scalp or brain; psychiatric illness, and history of drug abuse; pregnant women; signs of severity and/or indication of hospitalization; presence of previous rheumatic disease including gout, rheumatoid arthritis, fibromyalgia, lupus and others chronic pain syndromes with diagnosis prior to chikungunya
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain improvement in patients in the active group who received a 6-day treatment with tDCS by assessing the visual analog pain scale with a predicted improvement of 3 points for clinically perceptible outcomes
- Secondary Outcome Measures
Name Time Method Functionality improvement in patients in the active group who received 10-day treatment with tDCS assessing the HAQ functionality scale with a significant increase in their scor